Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 10/20 | 1.00 |
| ▸ | HTR2A | P28223 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 2/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31347241 | 1.00 | TAAR1 (1.00) | TAAR1HTR2ASMN1; SMN2MAPTNPSR1 | |
| Hydrochloric Acid SCHEMBL31031295 | 0.98 | TAAR1 (0.95) | TAAR1HTR2ASMN1; SMN2MAPTNPSR1 | |
| Hydrochloric Acid SCHEMBL1027288 | 0.98 | TAAR1 (0.95) | TAAR1HTR2ASMN1; SMN2MAPTNPSR1 | |
| SCHEMBL30505310 | 0.86 | TAAR1 (0.75) | TAAR1HTR2ATSHRACHE | |
| SCHEMBL3863804 | 0.86 | TAAR1 (0.75) | TAAR1HTR2ATSHRACHE | |
| SCHEMBL8324343 | 0.84 | TAAR1 (0.72) | TAAR1HTR2AHRH1 | |
| Hydrochloric Acid SCHEMBL1026697 | 0.84 | TAAR1 (0.72) | TAAR1HTR2ASMN1; SMN2MAPTNPSR1 | |
| SCHEMBL143962 | 0.84 | TAAR1 (0.71) | TAAR1SMN1; SMN2TSHRACHE | |
| SCHEMBL8498345 | 0.82 | TAAR1 (0.69) | TAAR1MAPTHRH1 | |
| SCHEMBL8498869 | 0.82 | TAAR1 (0.69) | TAAR1MAPTHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 658 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119638913-A | Flexible and easy-to-mold 3D printing photosensitive resin and preparation method thereof | 诺思贝瑞新材料科技（苏州）有限公司 | 2025-03-18 | — | — | CN | claimed |
| CN-119069802-A | Lithium-sulfur battery electrolyte composition, lithium-sulfur battery and application | 北京理工大学 | 2024-12-03 | — | — | CN | claimed |
| CN-117082953-A | Optoelectronic device and method for producing the same | 天合光能股份有限公司 | 2023-11-17 | — | — | CN | claimed |
| CN-109563085-B | Piperidine CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2022-08-09 | — | — | CN | claimed |
| US-20220064111-A1 | ENANTIOSELECTIVE SYNTHESIS OF BRIVARACETAM AND INTERMEDIATES THEREOF | CLININVENT RESEARCH PVT. LTD. (IN) | 2022-03-03 | — | — | US | claimed |
| EP-3490986-B1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-11-24 | — | — | EP | claimed |
| CN-113512029-A | Preparation and application of substituted pyrazole compound containing pyrimidinamine | 沈阳中化农药化工研发有限公司 | 2021-10-19 | — | — | CN | claimed |
| CN-112778739-A | Concentrated long-acting antibacterial anti-fouling PC master batch and preparation method thereof | 华东理工大学 | 2021-05-11 | — | — | CN | claimed |
| US-10752620-B2 | Piperdine CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2020-08-25 | — | — | US | claimed |
| US-20190169180-A1 | PIPERDINE CXCR7 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2019-06-06 | — | — | US | claimed |
| WO-2009043780-A1 | TETRAZOLE-SUBSTITUTED ARYL AMIDE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-09 | — | — | WO | claimed |
| EP-1971600-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK Holdings Co., Ltd. (KR) | 2008-09-24 | — | — | EP | claimed |
| EP-1590666-B1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH INC (US) | 2008-07-09 | — | — | EP | claimed |
| WO-2008048991-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-04-24 | — | — | WO | claimed |
| WO-2007078113-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK HOLDINGS CO., LTD. (KR) | 2007-07-12 | — | — | WO | claimed |
| EP-1590666-A4 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH INC (US) | 2006-07-26 | — | — | EP | claimed |
| EP-1590666-A1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | Genentech, Inc. (US) | 2005-11-02 | — | — | EP | claimed |
| CN-1558898-A | Antiviral agent | ��Ұ����ҩ��ʽ���� | 2004-12-29 | — | — | CN | claimed |
| US-20040171554-A1 | Compositions and methods for enhancing apoptosis | GENENTECH, INC. | 2004-09-02 | — | — | US | claimed |
| WO-2004072641-A1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH, INC. (US) | 2004-08-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064111-A1 | ENANTIOSELECTIVE SYNTHESIS OF BRIVARACETAM AND INTERMEDIATES THEREOF | CYP2B6, CYP3A4, CYP2C19 | TAAR1 1461/4885HTR2A 548/4885SMN1; SMN2 4760/4885 |
| US-20190169180-A1 | PIPERDINE CXCR7 RECEPTOR MODULATORS | CXCR1, CXCR5, ACKR3 | TAAR1 174/4885HTR2A 340/4885SMN1; SMN2 4095/4885 |
| US-10752620-B2 | Piperdine CXCR7 receptor modulators | CXCR1, CXCR5, ACKR3 | TAAR1 174/4885HTR2A 340/4885SMN1; SMN2 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.